Market Cap
€6.1b
Last Updated
2019/12/13 22:39 UTC
Data Sources
Company Financials +
Executive Summary
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has argenx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1AE's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
7.1%
1AE
6.2%
DE Biotechs
1.0%
DE Market
1 Year Return
59.6%
1AE
10.1%
DE Biotechs
14.2%
DE Market
Return vs Industry: 1AE exceeded the German Biotechs industry which returned 10.1% over the past year.
Return vs Market: 1AE exceeded the German Market which returned 14.2% over the past year.
Shareholder returns
| 1AE | Industry | Market | |
|---|---|---|---|
| 7 Day | 7.1% | 6.2% | 1.0% |
| 30 Day | 19.8% | 17.2% | 0.04% |
| 90 Day | 26.9% | 9.1% | 6.0% |
| 1 Year | 59.6%59.6% | 10.3%10.1% | 17.8%14.2% |
| 3 Year | n/a | 80.4%78.3% | 19.2%8.7% |
| 5 Year | n/a | 15.6%13.2% | 36.0%17.5% |
Price Volatility Vs. Market
How volatile is argenx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is argenx undervalued compared to its fair value and its price relative to the market?
8.15x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1AE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1AE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1AE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 1AE is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1AE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1AE is overvalued based on its PB Ratio (8.1x) compared to the DE Biotechs industry average (3.5x).
Next Steps
Future Growth
How is argenx forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
19.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1AE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1AE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1AE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1AE's revenue (57.5% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: 1AE's revenue (57.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1AE is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has argenx performed over the past 5 years?
-44.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1AE is currently unprofitable.
Growing Profit Margin: 1AE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1AE is unprofitable, and losses have increased over the past 5 years at a rate of -44.8% per year.
Accelerating Growth: Unable to compare 1AE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1AE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: 1AE has a negative Return on Equity (-15.07%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is argenx's financial position?
Financial Position Analysis
Short Term Liabilities: 1AE's short term assets (€959.9M) exceed its short term liabilities (€102.4M).
Long Term Liabilities: 1AE's short term assets (€959.9M) exceed its long term liabilities (€241.4M).
Debt to Equity History and Analysis
Debt Level: 1AE is debt free.
Reducing Debt: 1AE had no debt 5 years ago.
Balance Sheet
Inventory Level: 1AE has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 1AE's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 1AE has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 1AE is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 68.5% per year.
Next Steps
Dividend
What is argenx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 1AE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 1AE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1AE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1AE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1AE's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
What is the CEO of argenx's salary, the management and board of directors tenure and is there insider trading?
2.7yrs
Average management tenure
CEO
Tim Van Hauwermeiren (47yo)
11.4yrs
Tenure
€4,402,768
Compensation
Mr. Tim Van Hauwermeiren, MSc, EMBA, has been the Chief Executive Officer and Executive Director at argenx SE since July 2008 and July 9, 2014 respectively. Mr. Van Hauwermeiren co-founded Argenx SE in 200 ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD4.90M) is above average for companies of similar size in the German market ($USD3.71M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
2.7yrs
Average Tenure
55yo
Average Age
Experienced Management: 1AE's management team is considered experienced (2.7 years average tenure).
Board Age and Tenure
4.6yrs
Average Tenure
59.5yo
Average Age
Experienced Board: 1AE's board of directors are considered experienced (4.6 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chief Executive Officer CEO & Executive Director |
| Shares | 6,107 |
| Max Price | €117.19 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Executive Director |
| Shares | 18,205 |
| Max Price | €117.13 |
| Entity | Individual |
| Role | Chief Executive Officer CEO & Executive Director |
| Shares | 7,370 |
| Max Price | €92.05 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.1%.
Management Team
Eric Castaldi (55yo)
Chief Financial Officer
- Tenure: 5.7yrs
Dirk Marcel Beeusaert (55yo)
General Counsel
- Tenure: 2.7yrs
Tim Van Hauwermeiren (47yo)
CEO & Executive Director
- Tenure: 11.4yrs
- Compensation: €4.40m
Hans de Haard (59yo)
Chief Scientific Officer
- Tenure: 11.4yrs
Joke Comijn
Director Corporate Communications & Investor Relations (EU)
- Tenure: 0yrs
R. Woods (51yo)
Chief Operating Officer
- Tenure: 1.7yrs
Wim Parys
Chief Medical Officer
- Tenure: 0.9yrs
Arjen Lemmen
Vice President of Corporate Development & Strategy
- Tenure: 0.9yrs
Board Members
Don deBethizy (69yo)
Non-Executive Director
- Tenure: 4.6yrs
- Compensation: €497.40k
Peter K. Verhaeghe (61yo)
Chairman of the Board
- Tenure: 5.4yrs
- Compensation: €522.40k
Werner Lanthaler (51yo)
Vice-Chairperson
- Tenure: 0yrs
- Compensation: €499.90k
Tony Rosenberg (66yo)
Non-Executive Director
- Tenure: 2.7yrs
- Compensation: €487.40k
Pam Klein (58yo)
Non-Executive Director
- Tenure: 3.7yrs
- Compensation: €487.40k
Tim Van Hauwermeiren (47yo)
CEO & Executive Director
- Tenure: 11.4yrs
- Compensation: €4.40m
David Lacey (67yo)
Non-Executive Director
- Tenure: 5.4yrs
- Compensation: €494.90k
James Daly (58yo)
Non-Executive Director
- Tenure: 1.6yrs
- Compensation: €961.75k
Company Information
argenx SE's company bio, employee growth, exchange listings and data sources
Key Information
- Name: argenx SE
- Ticker: 1AE
- Exchange: DB
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €6.079b
- Shares outstanding: 42.72m
- Website: https://www.argenx.com
Number of Employees
Location
- argenx SE
- Willemstraat 5
- Breda
- Noord-Brabant
- 4811 AH
- Netherlands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ARGX | ENXTBR (Euronext Brussels) | Yes | Ordinary Shares | BE | EUR | Jul 2014 |
| 0QW0 | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | EUR | Jul 2014 |
| ARGN.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jul 2014 |
| ARGXB | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | EUR | Jul 2014 |
| 1AE | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 2014 |
| ARGX | NasdaqGS (Nasdaq Global Select) | American Depository Receipts | US | USD | May 2017 |
Biography
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead product candidates include Efga ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/13 22:39 |
| End of Day Share Price | 2019/12/13 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.